First AD

Second AD

AE Management for Combination Regimens in Advanced RCC

Please comment on dose reduction and treatment duration rates in the CLEAR study and real-world experience. (

What are the typical starting doses for lenvatinib and pembrolizumab in your practice?

What is your approach to dose reductions and reverting to higher doses in your practice?

What are some commonly observed adverse events with IO-TKI regimens?

What strategies do you implement to mitigate and monitor for common side effects?

What interventions help promote early AE detection and proactive mitigation?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC  

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes. 